The study of somatic variants from tumor genomes is fundamental to cancer research and clinical decision-making. However, existing data protection frameworks impose restrictions on the use and sharing of these variants in conjunction with sensitive germline information. To overcome these challenges, we developed GenomeAnonymizer, the first method to anonymize short-read DNA sequences from tumor-normal pairs. This generates Somatic Tumor Twins (STTs), an anonymized version of the original data that preserves the donor’s privacy while retaining somatic tumor information and sequencing noise. This method successfully removed all detectable germline variants from the 47 PCAWG-Pilot samples. We further demonstrate that Whole-Genome Sequencing (WGS) STTs preserve more than 98% of the original somatic variants, enabling reliable downstream analysis that replicates somatic-related findings from the original samples, including cancer driver genes, mutational signatures, and intratumor heterogeneity. Importantly, we also show that STTs can reproduce the identification of actionable genes and downstream clinical interpretations and decision-making. We generated a cancer cohort of STTs matched with synthetic clinical data that could be openly shared and used across projects and centers worldwide. This paradigm-shifting approach will accelerate discovery and clinical translation in oncology and enable the robust benchmarking of genome analysis and large-scale data infrastructures.
Type 2 diabetes (T2D) is a complex and clinically heterogeneous disease. Although clustering approaches have defined clinical subtypes, their genetic and molecular architectures remain poorly understood. Efforts using genome-wide association studies (GWAS) have been constrained by modest sample sizes and conservative significance thresholds, limiting subgroup resolution. Leveraging recent expansions in cohort scale and diversity, we developed a new analytical framework that integrates GWAS with Machine Learning and eXplainable Artificial Intelligence. Applied to the UK Biobank, this strategy enabled the first comprehensive genetic and molecular characterization of T2D subtypes, identifying 184 genes that define each subgroup’s molecular landscape and associated tissue profiles. In addition, the framework improved detection of T2D risk compared to current Polygenic Risk Scores. The findings underscore the importance of clinical stratification to uncover the complex pathophysiology of T2D and to pave the way for more precise prevention and treatment strategies.